Circulating thrombomodulin during radiation therapy of lung cancer

Martin Hauer-Jensen, Feng Ming Kong, Louis M. Fink, Mitchell S. Anscher

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The endothelial cell glycoprotein, thrombomodulin (TM), is an important physiological anticoagulant. TM is downregulated and released from the cell membrane into the circulation by ionizing radiation and during inflammation. The present study measured plasma TM in 17 patients before, during, and after radiation therapy of lung cancer: nine patients developed radiation pneumonitis, whereas eight matched patients did not. Plasma TM did not change significantly in patients who developed radiation pneumonitis. In contrast, patients who did not develop pneumonitis exhibited a moderate, but statistically significant, decrease in plasma TM antigen during the initial 1-2 weeks, with complete normalization towards the end of treatment. Our study suggests that decreased release of TM during the early phase of radiation therapy may be associated with reduced pulmonary toxicity. The use of plasma TM as a marker of pulmonary toxicity needs further study.

Original languageEnglish (US)
Pages (from-to)238-242
Number of pages5
JournalRadiation Oncology Investigations
Issue number4
StatePublished - Sep 20 1999


  • Lung cancer
  • Radiation injuries
  • Radiation pneumonitis
  • Thrombomodulin

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology
  • Radiation
  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Circulating thrombomodulin during radiation therapy of lung cancer'. Together they form a unique fingerprint.

Cite this